- Home
- CABA vs GAMB Comparison
CABA vs GAMB Comparison
Compare CABA & GAMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | GAMB |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | Jersey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 197.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CABA | GAMB |
|---|---|---|
| Price | $2.16 | $5.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $14.57 | $11.36 |
| AVG Volume (30 Days) | ★ 1.8M | 565.8K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $154,519,000.00 |
| Revenue This Year | N/A | $32.43 |
| Revenue Next Year | N/A | $12.72 |
| P/E Ratio | ★ N/A | $106.19 |
| Revenue Growth | N/A | ★ 24.21 |
| 52 Week Low | $0.99 | $4.60 |
| 52 Week High | $3.67 | $17.14 |
Technical Indicators
Market Signals| Indicator | CABA | GAMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 37.52 |
| Support Level | $2.08 | $5.24 |
| Resistance Level | $2.25 | $5.38 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.79 | 6.14 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.